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Genome-based exploration of the
specialized metabolic capacities of the
genus Rhodococcus
Ana Ceniceros1, Lubbert Dijkhuizen1*, Mirjan Petrusma1 and Marnix H. Medema2*
Abstract
Background: Bacteria of the genus Rhodococcus are well known for their ability to degrade a large range of organic
compounds. Some rhodococci are free-living, saprophytic bacteria; others are animal and plant pathogens. Recently,
several studies have shown that their genomes encode putative pathways for the synthesis of a large number of
specialized metabolites that are likely to be involved in microbe-microbe and host-microbe interactions. To systematically
explore the specialized metabolic potential of this genus, we here performed a comprehensive analysis of the biosynthetic
coding capacity across publicly available rhododoccal genomes, and compared these with those of several Mycobacterium
strains as well as that of their mutual close relative Amycolicicoccus subflavus.
Results: Comparative genomic analysis shows that most predicted biosynthetic gene cluster families in these strains are
clade-specific and lack any homology with gene clusters encoding the production of known natural products. Interestingly,
many of these clusters appear to encode the biosynthesis of lipopeptides, which may play key roles in the diverse
environments were rhodococci thrive, by acting as biosurfactants, pathogenicity factors or antimicrobials. We
also identified several gene cluster families that are universally shared among all three genera, which therefore may
have a more ‘primary’ role in their physiology. Inactivation of these clusters by mutagenesis might help to generate
weaker strains that can be used as live vaccines.
Conclusions: The genus Rhodococcus thus provides an interesting target for natural product discovery, in view of its
large and mostly uncharacterized biosynthetic repertoire, its relatively fast growth and the availability of effective
genetic tools for its genomic modification.
Keywords: Specialized metabolism, Natural products, Biosynthetic gene clusters, Rhodococcus, Mycobacterium
Background
Specialized metabolites, also known as secondary metab-
olites, are small molecules that are not essential for
growth and reproduction of the producer organism but
give them a survival advantage. One example is the
production of antibiotics, which inhibit the growth of
surrounding organisms competing for the same re-
sources. Specialized metabolites are applied in human
society in various ways [1–4] and comprise diverse classes
of chemicals, including polyketides, peptides (produced
either ribosomally or nonribosomally), saccharides, ter-
penes and alkaloids [5].
The bacterial genus that has been most extensively
studied for its capacity to produce such bioactive com-
pounds is Streptomyces. Streptomycetes are the source
of most of the natural antibiotics that are used in mod-
ern medicine [6]. Antibiotics were a revolution in medi-
cine, being the cure for many—until then—deadly
illnesses such as the plague, leprosy, tuberculosis or
syphilis. Unfortunately, many pathogenic bacteria have
developed resistance to antibiotics, in some cases even
to all antibiotics currently available [7]. Several large-
scale efforts are under way to find new antibiotic com-
pounds that can be used to fight these strains. However,
in many cases, these efforts suffer from frequent redis-
covery of compounds previously identified from other
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strains [8]. The development of bioinformatics tools to
analyse the growing amount of available bacterial gen-
omic sequence information has shown that the number
of biosynthetic gene clusters (BGCs) that may encode
pathways capable of producing specialized metabolites is
much greater than initially thought, even in strains that
were already known for their specialized metabolite rep-
ertoires [9, 10], but also in many other strains from a
wide range of taxonomic groups [11, 12].
One of the actinobacterial genera that has received
relatively little attention from the natural products
research community is Rhodococcus. Rhodococci are ac-
tinomycetes that contain mycolic acids in their cell walls;
they are closely related to the genus Mycobacterium,
host of hazardous pathogenic strains such as Mycobac-
terium tuberculosis and Mycobacterium leprae. Two
Rhodococcus species—Rhodococcus equi and Rhodococ-
cus fascians—are animal and plant pathogens, respect-
ively. Traditionally, Rhodococcus strains have been
studied for their capacity to degrade complex organic
compounds and many of them have been isolated from
chemically contaminated environments [13, 14]. A
recent study has shown that rhodococci not only have a
vast specialized catabolic repertoire, but also a large special-
ized anabolic repertoire: the genomes of four Rhodococcus
strains were shown to harbour a vast number of different
BGCs, including a strikingly high number of nonribosomal
peptide synthetase (NRPS)-encoding BGCs compared to
other actinobacteria [12]. NRPSs are modular enzymes, in
which each module adds a specific monomer to the peptide
backbone. NRPS modules contain at least an adenylation
domain (A) that determines the specificity for the substrate
and activates it to start the synthesis, a thiolation (T) or
peptide carrier protein (PCP) domain that binds covalently
to the activated residue and a condensation domain (C)
that elongates the peptidyl chain. Different types of C do-
mains catalyze different types of condensation reactions
[15]. Some NRPS assembly lines start with a special con-
densation domain, the C-Starter domain, which catalyzes
the acylation of the first residue of the peptidyl chain,
thereby synthetizing a lipopeptide [15]. The last module of
the NRPS usually contains a thioesterase module that re-
leases the final peptide chain [16].
Among the specialized metabolites previously de-
scribed in Rhodococcus, there are several siderophores:
the hydroxamate-type siderophores rhequichelin, hetero-
bactin, rhodochelin [17–19], and the catecholate-type
siderophore rhequibactin [20]. Additionally, multiple
Rhodococcus strains have also been reported to produce
antibiotics [21]. Four (groups of ) rhododoccal natural
products with antimicrobial activity have been described
in literature; lariantin peptide antibiotics with anti-
mycobacterial activity [22], the polyketide aurachin RE
from Rhodococcus erythropolis JCM 6824 (which has a
structure similar to that of aurachin C from the Gram-
negative organism Stigmatella aurantiaca [23, 24]), a
group of peptide antifungals named rhodopeptins [25]
and the recently described humimycins [26]. The gene
cluster responsible for the synthesis of rhodopeptins has
not yet been identified.
Here, we performed an extensive genomic analysis of
the biosynthetic potential of twenty Rhodococcus strains
with complete genome sequences available. In view of
the close phylogenetic distance that Rhodococcus has with
Mycobacterium, we also analyzed several Mycobacterium
strains: four free-living strains and three obligate patho-
gens. Also the only available complete genome sequence
from the newly discovered genus Amycolicicoccus [27],
which is a taxonomic relative of Rhodococcus and
Mycobacterium, was included, adding to a total of 28
strains. Based on a computational reconstruction of gene
cluster families (GCFs) in these strains, we found several
BGCs shared between all species that may play key roles
in survival in pathogenic strains and could therefore be
studied as potential drug targets, as well as clade-specific
clusters that have a high probability of synthesizing novel
natural products not previously described. Particularly, a
striking variety of putative lipopeptide BGCs was ob-
served. Most of the NRPSs in Rhodococcus strains contain
an N-terminal condensation domain that belongs to the
C-starter subfamily,; additionally, we found a range of dif-
ferent CoA-ligases encoded in NRPS BGCs that may be
involved in lipidation. Altogether, we provide a compre-
hensive overview of the genomic basis of Rhodococcus
specialized metabolic diversity and show that Rhodococcus
is a promising and thus far underexplored target genus for
natural product discovery, in view of the large num-
ber of unknown clusters present in their genomes
and the availability of techniques for genetic manipu-
lation of this genus [28].
Results and discussion
Rhodococcus has great potential for specialized metabolite
production
In order to establish a phylogenetic framework to under-
stand biosynthetic diversity in rhodococci and their rela-
tives, a 16S rRNA phylogenetic analysis was first performed
with all 28 selected strains and two Streptomyces species as
outgroups: the model organism Streptomyces coelicolor and
the industrial clavulanic acid producer Streptomyces clavuli-
gerus, both of which are well-known specialized metabolite
producers (Additional file 1: Figure S1). The tree shows a
structure that corresponds to the previously described para-
phyletic nature of the Rhodococcus genus [29, 30].
A computational analysis (using antiSMASH 3.0 + Clus-
terFinder [11, 31, 32]) of their biosynthetic capacity
showed a considerable number of BGCs in all 28 strains
(Fig. 1, Additional file 1 and Additional file 2). antiSMASH
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predicts gene clusters that belong to known biosynthetic
classes, while ClusterFinder searches for putative gene
clusters of unknown function based on observed local
protein domain frequencies [11, 33]. The strain with the
highest number of gene clusters (128 BGCs, out of which
32 belong to known families and 96 are putative
ClusterFinder-predicted BGCs) is Rhodococcus opacus R7,
which also has the largest genome with 10.1 Mb; it is
followed by Rhodococcus jostii RHA1 and the other R.
opacus strains. The strain with the fewest gene clusters
(M. leprae, with 15 BGCs, among which 9 are
ClusterFinder-predicted putative BGCs) has the smallest
genome with 3.3 Mb (Fig. 1a). Both in Mycobacterium and
Rhodococcus, pathogenic strains generally have a smaller
genome and a limited array of BGCs [34]. Obligate patho-
gens live inside a host, reducing the need to adapt to
sudden environmental changes; also, they probably en-
counter a smaller diversity of microbial competitors in
their environment compared to soil bacteria, which may
reduce the need of different biosynthetic and/or catabolic
pathways could contribute to genome minimization [35].
They still need a minimum arsenal of molecules to com-
pete for resources with the host they infect. For instance,
M. tuberculosis is known to require siderophores to cap-
ture iron, which is in most cases in low availability since
the host organism sequesters it for its own use [18, 20,
36]. These siderophores are therefore targets to treat
mycobacterial infections.
Interestingly, the percentage of ClusterFinder-predicted
putative clusters that are not assignable to a known type
of molecule is about 75% of the predicted BGCs in Rhodo-
coccus, compared to the 64% and 46% for S. coelicolor and
Fig. 1 Numbers and families of biosynthetic gene clusters (BGCs) detected in all studied strains, compared to the well-known producers S. coelicolor
and S. clavuligerus. Plant pathogens are marked in green, animal and opportunistic pathogens in orange and human pathogens in red. a Total number
of BGCs predicted by antiSMASH, including ClusterFinder. On top of each bar, numbers represent the size of each genome in Mb. b BGCs predicted
by antiSMASH to code for known families of biosynthetic pathways. On top of each bar, proportion of described gene clusters from each strain. It can
be observed that the proportion of NRPS BGCs in Rhodococcus compared to other types of molecules is much higher, especially in R. jostii RHA1 and
R. opacus strains. (T3PK: Type III polyketide. T2PK: Type II polyketide, T1PK = Type I polyketide, PK: Polyketide. NRP: nonribosomal peptide. RiPP: ribosomally
synthetized and posttranslationally modified peptide)
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S. clavuligerus respectively (Fig. 1b). These putative BGCs
contain diverse types of enzyme-coding genes, different
between each cluster. While ClusterFinder-predicted
BGCs have an inherent high uncertainty regarding their
biochemical function (which in some cases can also be
non-biosynthetic), this does indicate that these genomes
may encode unknown pathways for the biosynthesis or
modification of a large variety of thus far unknown
molecules.
Altogether, the above findings corroborate the study of
Doroghazi and collaborators [12], who have recently
studied a smaller number of rhodococcal and mycobac-
terial genomes; they noted that these genomes contain a
large number of putative BGCs, and that the NRPS vs
PKS (Polyketide synthase) ratio in rhodococci is higher
compared to that in other actinomycetes. Our results
show that these observations extend throughout the
Rhodococcus genus (Fig. 1). Indeed, most of the Rhodo-
coccus strains contain a range of NRPS-encoding gene
clusters but only one or two Type I PKS-encoding gene
clusters, and they do not contain any Type II or Type III
PKS clusters, except for the two strains of Rhodococcus
aethrivorans and Rhodococcus sp. AD45 that contain
one or two Type III PKSs.
One aim of this analysis was to identify highly conserved
biosynthetic pathways with an increased likelihood of be-
ing essential to rhodococcal and mycobacterial metabol-
ism and would thus present possible drug targets to
combat pathogenic strains; a second aim was to identify
gene clusters that are only present in one or a few strains,
which may encode biosynthetic pathways for the produc-
tion of novel bioactive compounds. For this purpose, we
used the BiG-SCAPE software (Navarro-Muñoz, Yeong,
Medema et al., in preparation) to construct a sequence
similarity network that categorizes the different GCFs,
thus providing a powerful visualization of shared and
strain-specific BGCs across all the studied strains (Fig.
2 and Additional file 3).
In order to more fully understand the evolutionary his-
tories of all studied strains that have led to the currently
observed BGC repertoires represented in the network
(Fig. 2), we used ancestral state reconstruction with
Count [37] to identify the most parsimonious BGC gain/
loss events (Additional file 1: Figure S2). For that analysis,
we used a total of 114 different BGCs: all families shared
between more than 7 strains, complemented by all
remaining NRPS BGCs (Additional file 2). Additional file 1:
Figure S2 shows which GCFs are conserved across lineages
and which ones are not. Twenty-four GCFs are jointly
present in the genomes of different strains ofMycobacterium
and Amycolicicoccus (which form a monophyletic clade), as
well as in Rhodococcus. Altogether, all Rhodococcus clades
share 36 GCFs, the previous 24 plus 12 more GCFs that are
only present in all Rhodococcus strains. Notably, it can be
observed that the branches leading to R. jostii RHA1
and the three strains from R. opacus show many pu-
tative GCF gain events (Additional file 1: Figure S2),
which indicates that ecological specialization of these
strains involved acquisition of several biosynthetic
pathways through horizontal gene transfer.
Shared GCFs may have essential functions and therefore
offer possible targets to combat pathogenic strains
A detailed analysis was performed on the GCFs shared
among more than seven strains, which amount to a total
of 37 GCFs. We reasoned that biosynthetic pathways
strongly conserved between Mycobacterium and Rhodo-
coccus may offer possible drug targets in pathogenic
strains from both genera, since their conservation sug-
gests that they are important for survival. A presence/
absence map of these 37 GCFs in each strain was con-
structed to provide an overview of these data (Fig. 3).
The vast majority of these GCFs have no experimen-
tally characterized members. Seven GCFs have members
that have been previously described in at least one
strain: 1) the Type I PKS cluster that contains the gene
pks13 catalyzes the last condensation step of mycolic
acid biosynthesis [38], which is present in all studied
strains. This cluster is grouped together in the network
with a saccharide cluster that may also be related to cell
wall biosynthesis: it encodes arabinogalactan biosyn-
thetic enzymes, family 2 glycosyltransferases and O-
antigen transporters; 2) the NRPS BGC encoding the
biosynthesis of the siderophore rhodochelin and
rhequichelin, present only in 11 Rhodococcus strains
[39]; 3) the carotenoid BGC [40], detected as
“Unknown” in Mycobacterium strains and Rhodococcus
sp. AD45; 4) the mycofactocin BGC, encoding the bio-
synthesis of a ribosomally synthesized and post-
translationally modified peptide of unknown function
that was initially discovered by bioinformatics analysis
[41, 42], and is only absent in M. leprae; 5) the hetero-
bactin gene cluster described in R. erythropolis PR4 and
present only in R. erythropolis strains, R. enclensis and R.
sp. AD45; 6) the butyrolactone gene cluster, detected by
the presence of an afsA homologue, encoding the main
biosynthetic enzyme of the γ-butyrolactone signalling
molecules known to be involved in the regulation of the
secondary metabolism in Streptomyces [43], which are
present in all Rhodococcus strains except for Rhodococcus
sp. AD45 and R. pyridinovorans SB309; 7) the NRPS en-
coding the biosynthesis of the siderophore rhequibactin,
only present in R. equi strains [20].
Five of the 37 GCFs are present in all strains from the
three genera studied; each of them is predicted to en-
code a biosynthetic pathway for molecules belonging to
a different family. One of them is the already mentioned
Type 1 PKS pks13, involved in mycolic acid biosynthesis
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[38]. All these organisms are known to possess mycolic
acids in their cell walls, including A. subflavus, but these
mycolic acids vary in their complexity [38, 44]. The GCF
called Terpene, which is also shared by all strains, in-
cludes a lycopene cyclase as well as genes encoding the
enzymes SufD and NifU, known to be involved in the
biosynthesis of iron-sulphur clusters, which are known
to be cofactors of various proteins [45]. The third uni-
versally shared GCF is the Saccharide-2 family; BGCs
that are members of this family contain genes for the
synthesis of menaquinone synthesis, which is also known
as vitamin K2 and, among other functions, plays a role
in the respiratory electron transport chains in bacteria.
It also is known to be an important factor in the latent
phase of infection in M. tuberculosis [46]. Two other
GCFs are shared between all species, for each of which
the function is less certain. One of them is predicted to
contain fatty acid BGCs encoding a fatty acid synthase
Fig. 2 Sequence similarity network relating the gene clusters detected by antiSMASH from all strains. Each cluster is represented by a square in
the case of Rhodococcus, as an ellipse in the case of Mycobacterium, or as an octagon in the case of Amycolicicoccus subflavus. The different shapes are
colour-coded for different BGC families with a colour scheme consistently applied in other figures as well. The upper part of the network represents
the group of GCFs shared across multiple strains; GCFs in the top row are present in all strains and therefore might be crucial for survival. The lower
part contains the clusters that are only present in a few or even only a single strain and that could lead to the production of novel compounds that
have not been found in other species. GCFs with known product and GCFs discussed in this work are marked with a circle and named
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(FAS); the other one (Other-1) contains BGCs that may
be involved in heme biosynthesis. Characterizing the
function and products of these clusters may lead to the
identification of novel targets to develop vaccines against
pathogenic strains such as M. tuberculosis, Mycobacterium
bovis, M. leprae, R. fascians or R. equi.
Another GCF present in all strains encodes predicted
saccharide-terpene hybrid clusters (indicated as Saccharide/
terpene (carotene) from now on). However, a closer ana-
lysis shows that these ‘hybrid’ clusters probably constitute
pairs of unrelated clusters that are adjacent on the
chromosome and are therefore (probably incorrectly)
assigned as ‘hybrid’ clusters by antiSMASH. Indeed, some
GCF members represent just the terpene cluster or just the
saccharide cluster.
Among the partially shared GCFs, it is worth mention-
ing that the Ectoine GCF and the NRPS-1 GCF are
present in all strains except for pathogenic mycobacteria.
Ectoine is an osmolyte that is produced in high salt con-
ditions as osmoprotectant [47]. This molecule therefore
does not seem essential for these three pathogenic
Mycobacterium strains as osmoprotectant. Besides an
Fig. 3 Presence/absence map representing the GCFs shared between more than seven strains. The strains are displayed horizontally in phylogenetic
order. Vertically, they were ordered using hierarchical clustering (see Methods for details). Coloured squares indicate the presence of the gene cluster
in a specific strain. Darker areas represent more than one copy of the cluster. Six GCFs are conserved across all genomes. Characterized clusters are marked
by a square
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NRPS, the NRPS-1 BGCs encode a probable multidrug
resistance transporter from the MFS family; the presence
of the transporter-encoding gene indicates that this gene
cluster may encode the biosynthetic pathway of a bio-
active molecule for which self-resistance is needed. The
NRPS has one module which contains an adenylation
domain without a clear substrate prediction and a pepti-
dyl carrier protein domain. Three other clusters of un-
known function (Other-4, Other-5 and Other-6) were
detected in all Rhodococcus strains, for which we were
unable to predict a function. A more detailed description
of these gene clusters can be found in Supplementary
Information 2 (Additional file 1).
Rhodococcus sp. AD45 and R. pyridinovorans SB3094 show
a possible high adaptation of their secondary metabolism
to their environment
Figure 3 shows that Rhodococcus sp. AD45 lacks nine
clusters from GCFs that have members in all its close
relatives: the Saccharide-5, Other-11, 12, 13, 17, 19,
21, and the Butyrolactone and the Rhequichelin/Rho-
dochelin gene clusters. This strain was isolated from
fresh water sediments and is able to use isoprene as sole
source of carbon [48]. However, its genome is not much
smaller than those of its closest relatives, the R. erythropo-
lis strains. Indeed, this is the third Rhodococcus strain for
which the majority of its BGCs belong to species-specific
GCFs (as will be further discussed later in this work),
which suggests that this strain has adapted to a very
specific environment by losing some otherwise con-
served gene clusters, and by gaining others, probably
through horizontal gene transfer from other strains in
its environment.
Intriguingly, the genome of Rhodococcus pyridinovorans
SB3094, which is the strain with the smallest genome of
all free-living rhodococci studied in this work (5.24 Mb),
shows a genomic duplication of a 366-kb region of its
chromosome covering four of its BGCs which have not
been characterized. The genus Rhodococcus is known to
contain a great redundancy of genes but duplication of
complete gene clusters has not been reported before [49].
Notably, in some industrial strains, copy number variation
of BGCs has been shown to lead to increased specialized
metabolite production [50]. A similar high-producing
phenotype may have driven this evolutionary event and its
fixation in a population; further experiments are required
to confirm this. The combination of a small genome and
duplication of 7% of it indicates that this strain is highly
specialized to its environment [34, 51]. This strain was iso-
lated from oil fields. In fact, the only NRPS cluster dupli-
cated (NRPS-17, see Fig. 4), which is only shared with R.
equi strains, has a C-starter domain, which is known to
acylate the first residue of the NRP [15], indicating that it
probably encodes the biosynthesis of a lipopeptide that
could potentially serve as biosurfactant. Surfactants are
compounds that decrease the surface tension of two fluids
and improve the availability of hydrophobic compounds
such as oil, which is probably key to the survival of this
strain. Interstingly, R. pyridinovorans is also the only strain
along with Rhodococcus sp. AD45 to lack a butyrolactone
BGC. This cluster is known to be very conserved in
Rhodococcus and is thought to play an important role in
this genus [12]; in streptomycetes, the γ-butyrolactone
molecules are known to be involved in the regulation of
their specialized metabolism.
NRPS clusters constitute the most dominant biosynthetic
class in rhodococci
NRPS clusters are highly represented in Rhodococcus ge-
nomes. NRPSs can synthesize a great variety of peptides;
more than 500 different precursors have been identified
that can be used by NRPSs, thus creating a highly-varied
array of compounds [16]. Each precursor amino acid
added is specified by the adenylation domain of an
NRPS module. Apart from this diversity of precursors,
the peptide can be modified after it is released from the
NRPS by other tailoring enzymes that produce signifi-
cant changes in the structure. In total, 79 distinctive
NRPS GCFs were found across all 28 strains. Only one
of them is shared with all strains, except for the patho-
genic Mycobacterium strains; the product of this shared
cluster is not known. Most of the NRPS clusters are
present only in one strain or only in a small group of re-
lated strains as is the case of the R. erythropolis clade, a
clade comprising R. opacus strains and R. jostii, and the
R. fascians clade (Fig. 5). In the case of R. fascians, it is
possible that these clusters are involved in pathogenicity,
as is believed to be the case for NRPS-31 (see Fig. 4)
which was described in R. fascians D188 [52]. Mutagenesis
and expression studies performed with this gene cluster
revealed that it plays a role in pathogenicity but is not es-
sential [52]. This cluster is located on the plasmid of this
strain, but the final product of the cluster and its
physiological role are still unknown. Interestingly, some
taxonomically distantly related species share BGCs: for ex-
ample, the genome of Rhodococcus enclensis NIO-1009
contains five NRPS BGCs (including the one for humimy-
cin B) that are otherwise only found in genomes belonging
to the Rhodococcus erythropolis group. Given the fact that
these BGCs are located in close proximity, a large-scale
horizontal gene transfer event might explain this. As R.
enclensis and R. erythropolis are found in similar habitats
(soils, sediments), this could be another example of how,
sometimes, BGC repertoires are shared within the same
ecosystem, and thereby correlate stronger with ecology
than with taxonomy [53].
A few NRPS gene clusters that have been described in
different strains of Rhodococcus represent siderophores
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in all cases, reflecting the importance of iron uptake for
these bacteria. The importance of iron in rhodococcal
physiology (and, arguably, in actinobacterial physiology
in general) is also corroborated by the different gene
clusters detected containing genes encoding the biosyn-
thesis of heme groups, porphyrin and iron-sulphur co-
factors. The gene cluster involved in the synthesis of one
important iron-scavenging molecule, the hydroxamate-
type siderophore rhodochelin, has been described in R.
jostii RHA1 [17]. This cluster was predicted in most
Rhodococcus strains. The corresponding gene cluster
from R. equi 103S was identified previously as respon-
sible for the synthesis of rhequichelin [18]. The encoded
protein sequences and gene order in the clusters are
very similar, and therefore they are grouped together in
our network. Some of the genes present in each cluster
vary between species and as described by Miranda-
Casaluengo et al. [18], three out of four adenylation do-
mains from the NRPSs are highly conserved between the
species with the only differences being two active site
residues in the second adenylation domain [18]. Another
hydroxamate-type siderophore in this case only
present in R. erythropolis strains, R. enclensis and in
R. sp. AD45, is heterobactin, described in R. erythro-
polis PR4 by Bosello and collaborators [19]; this is
grouped together with Rhequibactin IupS/IupT in
the network and has a structure similar to rhodoche-
lin (Additional file 1: Figure S3).
In the case of rhodochelin, further genes are involved
in its biosynthesis, located outside this gene cluster [17].
This NRPS gene cluster thus is a good example of how
very similar NRPS clusters can be responsible for the
production of different molecules. Another group of NRPS-
synthesized siderophores described from Rhodococcus is
constituted by the catecholate-type siderophore rhequibac-
tins synthesized by the rhequibactin BGC [20, 54]. These
siderophores were described in R. equi 103S and two differ-
ent NRPSs are involved in its biosynthesis, IupS and IupT; it
is thought to be used only in saprophytic growth, since its
deletion did not affect the pathogenicity but prevents the
growth of the strain as a free-living organism [20]. The iupU
gene was also described in this strain by Miranda-
Casaluengo et al. [20] and was believed to be related to
rhequibactin biosynthesis. The molecular product of this
pathway was predicted to be a non-soluble siderophore be-
lieved to have a function similar to mycobactin, which is cell
wall-bound and therefore not diffusible [36]. Recent work,
describing the Rhodococcus antibiotics humimycins, identi-
fied the iupU gene as encoding the NRPS responsible for
the synthesis of the molecule humimycin A [26]. Humimy-
cins were synthesized based on the predicted product of the
NRPS encoded by IupU and by another NRPS present in
the R. erythropolis genome (encoding the biosynthesis of a
variant, humimycin B). Both molecules showed potent
activity against methicillin-resistant Staphylococcus aureus
(MRSA), by targeting lipid II flippases [26]. The NRPSs con-
tain a C-starter domain, which indicated that the first resi-
due of the NRP is acylated. Therefore, a β-hydroxymyristic
acid was added to the N-terminal residue of the com-
pounds, but no further modification was done in the prod-
uct. It is not unthinkable that the actual natural products
are further modified by other enzymes encoded in these
BGCs (they contain a conserved amidohydrolase, an
N-Acyltransferase and a MbtH protein, and sometimes a
Fig. 4 Nonribosomal-peptide BGCs that are potentially interesting for further studies. The amino acid residues predicted to be selected by the
encoded NRPSs are indicated on top of each corresponding gene, and question marks indicate unknown substrates. The clusters shown are the
following: NRPS-2, unknown and conserved in most rhodococci; NRPS-5, which contains an NRPS architecture similar to the humimycin NRPS;
NRPS-17, a putative lipopeptide duplicated in the genome of R. pyridinovorans and present also in R. equi strains; NRPS-29 and 30, only present in
R. equi strains; NRPS-31, a cluster believed to be involved in pathogenicity in R. fascians
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Fig. 5 (See legend on next page.)
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dehydrogenase). While Miranda-Casaluengo et al. [20] show
that the expression of iupU is not controlled by iron, as is
normally the case for siderophores, its deletion does affect
growth of R. equi 103 s in low iron conditions when grow-
ing as a free-living organism. Of course, it remains very pos-
sible that IupU does synthesize a real, humimycin-like
antibiotic: for example, one or more intermediates of the
synthesis could be affecting the expression of rhequibactin,
which would provide an alternative explanation for the low-
iron phenotype of the knockout. Interestingly, yet another
NRPS GCF, NRPS-5 (see Fig. 4), which is present in all R.
erythropolis strains, has an NRPS with the same domain
architecture as the humimycin NRPSs, but with different
predicted substrates in modules 1, 3, 4, 6 and 7. This cluster
also contains a long chain fatty acid CoA-ligase-encoding
gene, as well as a mammalian cell entry (mce) operon.
Further experimental studies will be needed to verify
the natural physiological roles of each of these intri-
guing nonribosomal peptides.
Two mycobacterial GCFs encoding siderophore-
producing NRPSs were detected in our analysis, which
are responsible for the production of the hydroxamate-type
siderophore mycobactin and exochelin [36], respectively.
The second set of genes necessary for mycobactin biosyn-
thesis, located on a different locus, were only detected in
M. tuberculosis [55]. Mycobactin is known to be essential
for M. tuberculosis pathogenicity. It is hydrophobic and is
localized in the cell wall, and is thought to work together
with the siderophore carboxymycobactin, which is a soluble
siderophore [36]. It is believed that carboxymycobactin
transfers the iron to mycobactin, which is then reduced
from Fe3+ to Fe2+ and transported into the cytosol [36].
The transfer is thought to be mediated by the iron-
dependent membrane protein HupB [36]. The mycobactin
BGC was detected in every Mycobacterium strain except
forM. lepraeTN. Exochelin has been described inM. smeg-
matis [56]. In the genome annotations that we used, the
NRPS is encoded in only one ORF instead of two. FxbB
and FxbC are fused and the BGC containing this fused
NRPS was only detected in M. smegmatis.
The products of the other NRPS GCFs (71 in total) re-
main unknown, which suggests a great potential for
identifying novel nonribosomal peptides. The clusters
NRPS-29 and NRPS-30 (see Fig. 4) are only present in
the facultative horse pathogen R. equi. This strain has
also been described as a human opportunistic pathogen
with a pathogenicity mechanism similar to that of M.
tuberculosis, mainly infecting alveolar macrophages; this
has attracted large interest towards the strain [57]. Mu-
tational inactivation of these gene clusters, followed by
tests on infective abilities and survival of these mutants
in host cells, should clarify whether they can be used to
develop drugs that may target any of these enzymes, or
even a vaccine.
Putative lipopeptides
We observed that several of these NRPS gene clusters
contain individual fatty acid CoA-ligases/synthetases as
well as C-starter domains [15], suggesting that their final
products may be lipopeptides. Many of these peptides
are predicted to be rich in serine and threonine residues
(see examples in Fig. 4), although these predictions may
not be reliable given the distant relationship to any ade-
nylation domains with known specificity. Rhodococcus
strains seem to have a preference for lipopeptides
formed by a C-starter domain or the combination of C-
starter domain and an acyl CoA-ligase/synthetase, while
Mycobacterium strains have a bigger proportion of clus-
ters with a CoA-ligase and without C-starter domains
(Fig. 5). Lipopeptides include antibiotics, such as dapto-
mycin, the last major antibiotic that has been commer-
cialized [58]. However, lipopeptides have other functions
besides antibiotics: some function as surfactants, others
display haemolytic activity [59] and still others play a
role in establishing infection and/or biofilm formation
[60]. They are formed from a cyclic oligopeptide, non-ri-
bosomally synthesized, to which an acyl chain is at-
tached [61]. These compounds are known to have
different antimicrobial activity and toxicity depending on
the length of the acyl chain. The acyl chain can be at-
tached to the oligopeptide by different methods [62]:
through a stand-alone acyl-carrier protein (ACP) and
fatty acid ligase, as is the case of daptomycin, by a hybrid
NRPS/PKS enzyme containing an ACP and fatty acid lig-
ase domain as is the case for mycosubtilin, or by a spe-
cialized C-starter domain in the NRPS, as is the case for
surfactin. In the case of the calcium-dependent anti-
biotic from Streptomyces species, the fatty acid is synthe-
sized in a specific pathway (Fab enzymes encoded in the
CDA gene cluster and enzymes from the primary metab-
olism), and is then attached to a stand-alone ACP that
directly transfers the lipid to the condensation domain
of the NRPS where it is attached to the peptide [63]. Of
the 79 distinct NRPS GCFs found our analysis, 69 show
(See figure on previous page.)
Fig. 5 Presence/absence map showing all NRPS clusters in the different strains. White indicates absence of the cluster. Blue indicates presence of
a gene cluster containing a C-starter domain in at least one of the NRPSs, which indicates that it encodes the biosynthetic pathway for a lipopeptide.
Yellow indicates presence of a NRPS cluster containing an acyl CoA-ligase/synthetase, also indicative of the final product being a lipopeptide. Green
indicates presence of NRPS clusters containing both one or more acyl CoA ligases/synthetases and a C-starter domain in one of the NRPS. Red indicates
presence of NRPS clusters not predicted to synthesize lipopeptides
Ceniceros et al. BMC Genomics  (2017) 18:593 Page 10 of 16
hallmarks of encoding the biosynthesis of lipopeptides.
Also, all rhodococcal genomes studied encode putative
lipopeptide BGCs, regardless of their specific ecological
diversity. Still, the wide variety of bioactivities known to
be associated with lipopeptides explains why they are
likely to be important in various niches: They may aid
the infection process in pathogenic strains or function as
antibiotics in saprophytic ones. To zoom in on the bio-
synthetic diversity of lipopeptides encoded in rhodococ-
cal genomes, we performed a detailed analysis of the
fatty acid CoA-ligases and synthetases encoded in NRPS
clusters. Out of the 79 GCFs, 19 encoded distinct CoA-
ligases that may be involved in lipopeptide biosynthesis
[13, 64]. Notably, such ligases may also be encoded out-
side the cluster: for example, the enzymes in charge of
the transfer of the acyl chain to the peptide part of
mycobactin are in different loci as the peptide synthe-
tases [55]. A phylogenetic study of these enzymes,
comparing them to previously described fatty acid
CoA-ligases involved in the synthesis of characterized
lipopeptides (Additional file 1: Figure S4), highlights
their diversity.
Given the fact that such a wide variety of rhododoccal
lipopeptide BGCs exists, we hypothesize that they have
adapted to specific ecological sub-functions during evo-
lution. If this indeed is the case, we predict that a dy-
namic evolution of lipopeptide BGC repertoires has
occurred. In order to study this dynamic evolution, we
performed ancestral state reconstruction of the 67 clus-
ters using the software Count [37] to identify GCF gain/
loss events across the evolutionary history of the
Rhodococcus genus (Additional file 1: Figure S5). Indeed,
the vast majority of putative lipopeptide GCFs showed a
taxon-specific distribution. None are conserved through-
out Mycobacterium and Rhodococcus, but NRPS-2 and
rhequibactin IupS/IupT are present in several strains of
Rhodococcus and in A. subflavus (Figs. 3 and 4). The
clade with the largest number of predicted lipopeptides
is the one containing R. jostii RHA1 and the three R.
opacus strains. With 17 putative lipopeptide BGCs, R.
opacus P630 contains the largest number, followed by R.
jostii RHA1 with 15 putative lipopeptide BGCs. The
other Rhodococcus clades harbour between three and
eight putative lipopeptide BGCs per genome. The R. jostii
RHA1 and R. opacus PD630 and B4 strains have been
studied for their ability to accumulate carbon in triacycl-
glycerols (TAGs) when growing in nitrogen limited media
and using different carbon sources [49, 65, 66]. Alvarez et
al. [65] have shown a higher triacyclglycerol accumulation
when using gluconic acid as the sole carbon source and
an even higher production in the case of strain PD630
when grown in olive oil [49, 65]. Lipopeptide surfactants
might facilitate degradation of the hydrophobic com-
pounds present in their growth media, allowing their
import into the TAG biosynthesis pathway. Interest-
ingly, M. tuberculosis has five putative lipopeptide
GCFs (NRPS-15, NRPS-26, NRPS-27, NRPS-28 and
NRPS-8), in addition to mycobactin, making it the
Mycobacterium strain with the largest number of lipo-
peptides; it should be noted though, that all of these
lipopeptides are predicted as such based on the pres-
ence of a CoA-ligase-encoding genes, which could
also have a different enzymological role (and hence is
a ‘weaker’ marker for peptide lipidation then C-starter
domains are). Also, NRPS-26 and NRPS-28 are not
canonical NRPS clusters; they do not possess a modular
NRPS enzyme but stand-alone domains usually found in
modular enzymes, as described in Wang et al. [67]. Lipo-
peptides are known to induce a strong immune response
and many of them have remained uncharacterized [68,
69]. The products of these putative lipopeptide BGCs
might allow development of vaccines against M. tubercu-
losis by inducing a response of the host immune system.
Many rhodococci and mycobacteria contain strain-specific
GCFs
Every strain except for M. tuberculosis has strain-specific
GCFs (Fig. 6). M. tuberculosis shares all its GFCs with at
least one other strain, in many cases with M. bovis. The
M. smegmatis and A. subflavus strains display the high-
est number of strain-specific GCFs (about 65%) followed
by M. vanbaalenii and R. fascians A44. A. The number
of shared BGCs will depend, of course, on how closely
related one species is to the rest of the studied strains.
A. subflavus is the only strain of its genus studied, there-
fore it was expected that it would have many strain-
specific GCFs. On the contrary, this was not expected
for the R. fascians strains. R. fascians A44A has almost
50% of strain-specific clusters, while only 10% and 23%
of the GCFs from R. fascians D188 and R. fascians LMG
2536, respectively, are species-specific. Creason et al.
previously indicated that R. fascians A44A is relatively
distantly related to the other R. fascians strains [70].
Possibly, these differences are also responsible for host
range specialization among members of this phyto-
pathogenic species, as well as differences in the symp-
toms caused.
Another interesting observation is that most GCFs
present on plasmids are unique to the species they are
found in. This is true in the cases of R. jostii RHA1, R.
erythropolis R138, all three strains of R. opacus and R.
pyridinovorans SB3094. Plasmids are mobile and there-
fore the BGCs encoded on them might be expected to
have homologues in more than one species. To find out
whether these clusters are shared with other strains,
which also may indicate which strains share the same
habitat, R. jostii RHA1 was studied in more detail.
Fifteen out of the 35 non-shared clusters were found to
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be present on the plasmids of R. jostii RHA1. This spe-
cies has a total of 18 clusters on its three plasmids, thus
most of them are not shared with the rest of the species
in this study, not even with its closest relative R. opacus.
The number of strain-specific clusters present on the
plasmids of R. jostii RHA1 is comparable to that in R.
opacus R7, which has 11 strain-specific clusters on its
plasmids from 37 non-shared of a total of 128 predicted
gene clusters. This number is much higher than the
number of strain-specific clusters present on the plasmids
of their close relatives R. opacus PD680 and R. opacus B4:
only three strain-specific clusters are present on the plas-
mids of R. opacus PD680 and five in R. opacus B4. Due to
the previously mentioned special nature of the R. pyridi-
novorans SB3094 genome, which is small and has a
366 kb duplication, we also analyzed the two BGCs pre-
dicted on its plasmid. Homologs of the enzyme-coding
genes in both these clusters were also found in other rho-
dococci isolated from oil-contaminated soil, soil, waste
water, and even in Rhodococcus gordonia, which has been
isolated from clinical material and phenol-contaminated
soil. This suggests that indeed these BGCs may confer
specific traits to the strain that allow it to thrive in such
conditions. Experimental studies are needed to further
characterize these clusters.
Activation of cryptic BGCs may allow discovery of new
bioactive compounds
As presented in this work, most BGCs identified in the
different strains studied here are completely unknown.
Various methods have been developed to induce the ex-
pression of such BGCs. Some of these approaches are the
deletion of known biosynthetic pathways to make precur-
sors available for other routes [71], the co-cultivation of
two or more strains [72], the manipulation of regulatory
systems [73, 74] or the heterologous expression in other
strains [75]. In some cases, introduction of synthetic
promoters may be needed to enforce BGC expression in
the heterologous host [76]. These and other synthetic biol-
ogy techniques can be used for the activation of cryptic
metabolic routes; the final goal of synthetic biology in this
context is to be able to design molecules by combining
different regulatory elements and biosynthetic genes
(building blocks) [77, 78]. As such, it has the potential to
allow for the refactoring as well as further engineering of
cryptic gene clusters such as those studied in this paper.
Powered by such technologies, the secondary metabolism
from Rhodococcus can hopefully be used to identify targets
to fight related pathogenic strains as well as to identify
and engineer novel bioactive natural products.
Conclusions
Rhodococci harbour a great number of putative biosyn-
thetic gene clusters in their genome, most of them of
unknown product. These include a considerable number
of biosynthetic gene clusters that putatively encode the
production of lipopeptides, which can have diverse
functions, ranging from biosurfactants to antibiotics.
Rhodococcus strains also share several BGCs of un-
known function with free-living and pathogenic
strains of Mycobacterium. This genus is therefore in-
teresting to explore for finding new natural products
as well as finding conserved pathways that could be
used as targets to fight pathogenic strains.
Methods
Software
Links and references to the software used in this study
can be found in Additional file 4.
AntiSMASH analysis
Genome sequences were obtained from NCBI (http://
www.ncbi.nlm.nih.gov) and analysed with antiSMASH,
Fig. 6 Percentage of strain-specific gene clusters from all detected GCFs present in each strain. M. tuberculosis is the only one that shares all its
BGCs with other species, while M. smegmatis and A. subflavus only share 38.1% and 36.2% of their BGCs with the other strains studied. The number of
gene clusters not shared by R. fascians A44A (46.4%) compared to its close relatives R. fascians LMG2536 (23.6%) and R. fascians D188 (10.3) is also striking
but explained by their presence in different clades in the phylogenetic tree (Additional file 1: Figure S1), also observed in [70]
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which was run with default settings plus inclusion of the
ClusterFinder algorithm (http://antiSMASH.secondaryme
tabolites.org). Results can be accessed in Additional file 5.
16S rRNA phylogenetic tree
16S ribosomal RNA sequences were obtained from
NCBI. In the case of species that contain more than one
16S rRNA genes, only one of them was included in the
phylogenetic analysis since all of them appeared together
in the tree. The analysis was performed which was per-
formed using MEGA 6.0 [79] (http://www.megasoftware.
net/). Multiple-sequence alignment was performed using
MUSCLE with default parameters; a phylogenetic tree was
generated using the Neighbour-Joining method and the
bootstrap test with 1000 replicates.
Phylogenetic tree of acyl-CoA ligases involved in the
synthesis of lipopeptides
All acyl-CoA ligases present in all gene clusters detected
by antiSMASH were identified by sequence homology
(using the AMP-binding Pfam domain and BLAST quer-
ies against known CoA-ligases from MIBiG, see below).
Acyl-CoA ligases not present in NRPS gene clusters and
the ones corresponding to NRPSs adenylation domains
were discarded for the analysis. A set of known acyl-
CoA ligases involved in synthesis of lipopeptides were
obtained from the MiBIG database and added to the
analysis. Protein sequence alignment was performed
using PROMALS3D. Phylogenetic analysis was per-
formed using MEGA 6.0 the Neighbour-Joining method
and the bootstrap test with 1000 replicates.
BGC similarity networks and gene cluster family
reconstruction
A network containing 2363 nodes was generated using
BiG-SCAPE (https://git.wageningenur.nl/medema-group/
BiG-SCAPE), with parameters optimized for a good separ-
ation of NRPS clusters (see Additional file 3). The parame-
ters used were Jaccard index (0.2), similarity of domain
order measured by the Goodman-Kruskal γ index (0.05)
and the domain duplication similarity, weighted by se-
quence identity (0.75). Six network versions were pro-
duced with different cut-offs of 0.60, 0.65, 0.70, 0.75, 0.80
and 0.85. The lower the cut-off, the fewer connections are
kept between the clusters. Based on manual inspection of
connections to known BGCs at various versions of the
network, a cut-off of 0.75 was chosen for the final analysis.
Analysis of the network
Groups of gene clusters with more than 7 nodes were
curated manually based on inspection of the results of
multi-gene homology searches with MultiGeneBlast
(http://multigeneblast.sourceforge.net/) to confirm that
they indeed constitute a valid GCF. Gene clusters of
known molecular class but unknown final product
(NRPs, PKs, RiPPs, etc.) were considered as the same
cluster when the identity of the main biosynthetic en-
zymes was 60% or higher inside the same genus and
50% from different genera, given the lower identity ex-
pected between distinct genera. If no core scaffold bio-
synthesis enzymes could be identified in BGCs within a
connected component, the organization predicted in the
network was considered correct. Known and described
GCFs were also curated manually with MultiGeneBlast
and added or removed when required. Additional file 2
contains an overview of curated GCFs.
Gain/loss diagrams
The gain/loss diagram was created using Count [37]. A
total of 112 GFCs (GCFs shared with more than 7
strains and all predicted NRPSs) were used as input.
Dollo parsimony and Wagner parsimony (gain penalty: 1)
were used for the analysis.
Presence/absence map generation
The Python Module Seaborn was used to generate the
presence/absence map of GCF absence/presence across
genomes. Pairwise distances were calculated using the
Euclidean method, the hierarchical clustering of the gene
clusters was performed with the Complete method.
Strains were ordered according to their appearance in
the 16S–rRNA based phylogenetic tree. In cases of
strains containing more than one 16S rRNA gene, they
were checked for consistent signal and the first occur-
ring 16S rRNA in each strain chromosome was used to
generate the phylogenetic tree from the presence/ab-
sence map and the three R. opacus strains which have 44
to 45 BGCs.
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